In particular, CDKL2 is overexpressed in mesenchymal breast cancer cells compared with epithelial cells, and its overexpression is negatively correlated with disease‐free survival.23 In summary, the described studies have revealed crucial roles of CDKLs in EMT and carcinogenesis and suggested that CDKLs could be potential biomarkers for prognosis as well as gene targets for cancer therapy. Here, CDKL2 is linked to breast carcinoma.